NAS:PTCT (USA) Also Trade In: Germany

PTC Therapeutics Inc $ 63.36 0.31 (0.49%)

Avg Vol (1m):
Market Cap $:
4.32 Bil
Enterprise Value $:
3.60 Bil
P/E (TTM):
Warning! GuruFocus has detected 4 Severe warning signs with PTCT. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

PTC Therapeutics Inc News and Headlines -

GuruFocus Articles Total 9
  • 1

Biotech's shares trading near all-time high of $172. It is also working on Covid-19 treatment

On the heels of research deals with two small biotechs, shares of Sarepta Therapeutics Inc. (SRPT) hit their all-time high of more than $172 on June 23.

The share price of the Cambridge, Massachusetts-based biopharmaceutical company has doubled since mid-March. It has a market cap of more than $13 billion.

Sarepta has made a host of deals in the past several years that have made gene therapy a key part of its business, which had been dominated by drugs for muscular dystrophy. One of those pacts, with Roche (RHHBY), could be worth more than $3 billion.

Sarepta currently has a

165 Views    Barry Cohen    2020-06-23 19:05
Stock basically flat after company reveals it will test cancer drug for coronavirus

Investors have either become overwhelmed by the number of companies entering the quest to address Covid-19 or are having difficulty separating the wheat from the chaff. Either way, the latest entrant to the coronavirus battle was met with a big ho-hum.

On the announcement that it was going to test its early-stage cancer drug against the virus, PTC Therapeutics Inc. (PTCT) shares gained two cents to just under $50.36.

The New Jersey-based biotech is set to launch a two-step, phase 2 and 3 trial of the leukemia drug PTC299 in the United States, with additional tests requested in Spain and

83 Views    Barry Cohen    2020-06-18 20:53
PTC Therapeutics makes the list

According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.

Integer Holdings Corp. (ITGR) is held by nine gurus

The medical devices and components manufacturer has a market cap of $2.66 billion. Its revenue of $1.23 billion has grown 5.40% over a 10-year period.

The stock is trading with a price-earnings ratio of 14.60. The share price of $81.8 is 11.29% below the 52-week high and 24.10% above the 52-week low. Over the last 10 years, it has returned 325%.

The company’s largest shareholder among the gurus is Ken Fisher (Trades,

160 Views    Tiziano Frateschi    2019-07-10 20:41
The largest Insider Buys this week were Delta Air Lines, DISH Network, IberiaBank and PTC Therapeutics

The largest Insider Buys this week were for Delta Air Lines Inc. (DAL), DISH Network Corp. (DISH), IBERIABANK Corp. (IBKC), and PTC Therapeutics Inc. (PTCT).

Delta director bought 5,185 shares

Director Francis S. Blake bought 5,185 shares of Delta on Jan. 28 for an average price of $48.17 per share. The stock price has increased 3.63% since then.

Delta is a major American airline, operating over 5,400 flights daily. The company has a market capitalization of $34.23 billion; as of Feb. 1, it traded at $49.92.

On Jan. 15, the company reported fourth-quarter and full-year 2018 results. GAAP pretax income

402 Views    Shuda Xia    2019-02-01 22:53
PTC Therapeutics, Baytex Energy rise on clinical results and acquisition news

Shares of PTC Therapeutics Inc. (PTCT) jumped on Monday on positive results from its open-label FIREFISH study evaluating risdiplam (RG7916) in babies with type 1 spinal muscular atrophy. Over 90% of the babies treated with risdiplam, a splicing modifier that targets the survival motor neuron 2 RNA, achieved more than a four-point increase in a test of motor skills called CHOP-INTEND. The median increase was 5.5 points.

"We are delighted that up to 6.5-fold increase of protein production has translated into clinical impact for these babies in the FIREFISH study," CEO Stuart W. Peltz, Ph.D., said. "The survival data and

55 Views    Omar Venerio    2018-06-18 22:10
Insider purchased 800,000 shares

Insider Peter Svennilson purchased 800,000 shares of Immune Design (IMDZ) on Sept. 19 at $6.25 per share, according to a Form 4Â filing for the Securities and Exchange Commission.

Since the trade, Immune Design’s market price has gained an estimated 21.28%.

Immune Design Corp. has a market cap of $152.94 million, an enterprise value of $52.11 million, a price-book (P/B) ratio of 1.76, a current ratio of 17.61 and a quick ratio of 17.49.

Immune Design Corp. is a clinical-stage immunotherapy company. The company is focused in oncology and engineers its technologies to activate

689 Views    Kyle Ferguson    2016-10-03 16:19
He sells stakes in Time Warner Cable and International Game Technology

Michael Price (Trades, Portfolio), who manages private firm MFP Investors, is a value investor who looks for out-of-favor small cap companies with good value. His most significant second-quarter acquisition was a 1,625,000-share stake in Kearny Financial Corp. (KRNY), a holding company for Fairfield, N.J.-based Kearny Federal Savings Bank. He paid an average price of $10.42 per share in a deal that had a 2.39% impact on his portfolio.

Kearny Financial has a market cap of $1.05 billion and an enterprise value of $1.6 billion. It has a P/E of 90.6, a Price/Book of 2.1 and a Price/Sales

1470 Views    David Goodloe    2015-09-02 22:32

By Sarah Roden

The American Association of Neurology is hosting its annual meeting this week in Washington, DC. Through the end of this week, major biotechnology companies will be making presentations highlighting drug breakthroughs and updates. Analysts at Cowen & Co., led by Ritu Baral, highlighted what to watch for when several companies present at the annual meeting.

Biogen Inc (BIIB)

Cowen expects Biogen’s presentation at the AAN meeting to garner the highest level of investor focus. Baral expects Biogen to provide incremental data on aducanumab (BIIB037), a drug intended to treat Alzheimer’s disease. BIIB037 slows the growth

1250 Views    TipRanks    2015-04-22 20:36
One biotech has seen [url=]intensive insider buying[/url] during the last 30 days. Intensive insider buying can be defined by the following three criteria: The stock is purchased by three or more insiders within one month. The stock is sold by no insiders in the month of intensive purchasing. At least two purchasers increase their holdings by more than 10%. [b]Fate Therapeutics[/b] ([url=]FATE[/url]), a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. [i][url=][img][/img][/url][/i] [b]Insider Buying During the Last 30 Days[/b] Here is a table of Fate Therapeutics' insider-trading activity during the last 30
789 Views    Markus Aarnio    2013-10-09 15:20

Headlines Total 37
  • 1

2021-01-23 $ 63.36 (%)
2021-01-20 $ 63.795 (-2.78%)
2021-01-12 $ 67.05 (1.18%)
2020-12-31 $ 61.03 (-0.08%)
2020-12-10 $ 61.99 (-3.06%)
2020-11-06 $ 59.38 (0.1%)
2020-11-04 $ 56.87 (3.36%)
2020-10-30 $ 52.19 (-3.15%)
2020-10-29 $ 53.89 (2.71%)
2020-10-22 $ 51.98 (1.48%)
2020-10-09 $ 53.81 (1.39%)
2020-10-08 $ 53.61 (8%)
2020-09-30 $ 46.75 (-1.1%)
2020-08-28 $ 48.75 (1.08%)
2020-08-27 $ 48.23 (0.73%)
2020-08-18 $ 49.13 (-2.6%)
2020-08-08 $ 47.83 (1.72%)
2020-08-05 $ 48.97 (0.99%)
2020-07-29 $ 47.03 (-1.9%)
2020-07-17 $ 55.7 (1%)
2020-06-18 $ 50.36 (0.04%)
2020-06-03 $ 49.93 (-2%)
2020-05-22 $ 50.61 (1.34%)
2020-05-18 $ 49.64 (1.66%)
2020-05-07 $ 46.91 (-2.72%)
2020-05-01 $ 48 (-5.73%)
2020-04-30 $ 50.92 (-4.89%)
2020-04-23 $ 49.4 (-0.72%)
2020-04-08 $ 44.15 (3.18%)
2019-12-26 $ 48.93 (-1.61%)
2019-12-05 $ 49.43 (-1.28%)
2018-10-23 $ 36.97 (-0.51%)
2015-04-22 $ 70.98 (%)
Total 37
  • 1